Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc. (DNA): 1 pipeline candidate · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.5 months
D/E 1.33 · 0% dilution
Lead: Approved
1 candidate
N/A
0 buys · 13 sells (180d)
A transparent, data-derived signal for Ginkgo Bioworks Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$537.6M
Cash
$188.7M
Quarterly Burn
$46.4M
Runway
16.5 mo
Revenue
$19.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| sodium | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
172
Total value held
$184.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,828,856 | $23.5M |
| blackrock, inc. | 3,642,347 | $22.3M |
| viking global investors lp | 3,577,128 | $21.9M |
| anchorage capital group, l.l.c. | 1,746,363 | $10.7M |
| legal & general group plc | 1,661,587 | $10.2M |
| state street corp | 1,346,659 | $8.3M |
| forbes j m & co llp | 1,028,391 | $6.3M |
| geode capital management, llc | 1,009,362 | $6.2M |
| goldman sachs group inc | 929,862 | $5.7M |
| allianz asset management gmbh | 700,516 | $4.3M |
Showing top 10 of 172 institutional holders of Ginkgo Bioworks Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Ginkgo Bioworks Holdings Inc.'s pipeline?
Ginkgo Bioworks Holdings Inc. (DNA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ginkgo Bioworks Holdings Inc.'s lead drug candidate?
Ginkgo Bioworks Holdings Inc.'s most advanced tracked candidate is sodium (Approved) for Uses temporarily relieves minor aches and pains due to: minor pain of arthritis muscular aches backache menstrual cramps headache toothache the common cold temporarily reduces fever.
What is Ginkgo Bioworks Holdings Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ginkgo Bioworks Holdings Inc. has approximately 16.5 months of cash runway.
What is Ginkgo Bioworks Holdings Inc.'s market capitalization?
Ginkgo Bioworks Holdings Inc.'s market capitalization is approximately $537.6M.
Who is the CEO of Ginkgo Bioworks Holdings Inc.?
Dr. Jason Kelly Ph.D. is the chief executive officer of Ginkgo Bioworks Holdings Inc. (DNA).
Get the full picture on Ginkgo Bioworks Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.